Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M9QZ
|
|||
| Former ID |
DCL000029
|
|||
| Drug Name |
ABT-869
|
|||
| Synonyms |
Linifanib; ABT 869; S1003_Selleck; AL-39324; RG-3635; ABT869, Linifanib, AL-39324, RG3635; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 3 | [1], [2], [3] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Abbott Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H18FN5O
|
|||
| Canonical SMILES |
CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N
|
|||
| InChI |
1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)
|
|||
| InChIKey |
MPVGZUGXCQEXTM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 796967-16-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16587270, 23620132, 42564545, 49689152, 50100086, 79067798, 99431596, 99431769, 103510213, 103904340, 121279556, 124490375, 124756926, 124772088, 125163733, 125334020, 126584078, 126636388, 126666451, 126728314, 131465097, 131477691, 134338740, 134964215, 135253632, 135685203, 135685207, 135685211, 135693528, 135723697, 136340278, 136368138, 136920256, 137262629, 137275904, 141225545, 143498888, 144115529, 152058517, 152234947, 152258823, 152344118, 160647674, 162011552, 162037378, 162118069, 162202645, 163124954, 164041875, 164761586
|
|||
| ChEBI ID |
CHEBI:91435
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor receptor 3 (FLT-4) | Target Info | Modulator | [2], [4] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Focal adhesion | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Pathway Interaction Database | VEGF and VEGFR signaling network | |||
| VEGFR3 signaling in lymphatic endothelium | ||||
| Reactome | VEGF binds to VEGFR leading to receptor dimerization | |||
| WikiPathways | Signaling by VEGF | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5657). | |||
| REF 2 | Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006. | |||
| REF 3 | Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 2006 Apr;5(4):1007-13. | |||
| REF 4 | Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 2006 Apr;5(4):1007-13. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.